Table 1:
Patient and Treatment Characteristics in Development and Validation Cohorts
| Variable | Category | Development cohort |
Validation cohort |
P value |
|---|---|---|---|---|
| N=750 (100%) | N=369 (100%) | |||
| Socio-demographic variables | ||||
| Age | Mean (SD) | 73.1 (6.0) | 77.2 (5.2) | <0.01 |
| Gender | Male | 331 (44.1%) | 202 (54.7%) | <0.01 |
| Female | 419 (55.9%) | 166 (45.3%) | ||
| Race | White | 632 (84.3%) | 350 (95.1%) | <0.01 |
| | Black | 62 (8.3%) | 12 (3.3%) | |
| Others | 56 (7.5%) | 6 (1.6%) | ||
| Education | High school or less | 289 (38.5%) | 178 (48.3%) | <0.01 |
| College or above | 470 (61.4%) | 290 (51.5%) | ||
| Baseline clinical variables | ||||
| Cancer type | GI | 203 (27.1%) | 114 (30.9%) | <0.01 |
| Lung | 207 (27.6%) | 116 (31.4%) | ||
| GU | 80 (10.7%) | 53 (15.2%) | ||
| Others | 260 (34.7%) | 86 (23.3%) | ||
| Cancer stage | Stage 1 | 33 (4.4%) | -- | -- |
| Stage 2 | 99 (13.2%) | -- | ||
| Stage 3 | 175 (23.3%) | 35 (9.5%) | ||
| Stage 4 | 436 (58.1%) | 324 (87.8%) | ||
| Line of chemotherapy | First line | 531 (70.8%) | 275 (74.5%) | 0.19 |
| Second line or more | 219 (29.2%) | 94 (25.5%) | ||
| Standard chemotherapy | Yes | 548 (73.1%) | 240 (65.0%) | <0.01 |
| No | 177 (23.6%) | 129 (35.0%) | ||
| Number of chemotherapy agents | Single | 223 (29.7%) | 174 (47.3%) | <0.01 |
| Poly | 527 (70.3%) | 194 (52.7%) | ||
| Geriatric assessment and laboratory variables | ||||
| Falls in past 6 months | yes | 145 (19.4%) | 76 (20.7%) | 0.26 |
| no | 603 (80.6%) | 292 (79.3%) | ||
| Number of comorbidities | Median (range) | 2 (0-12) | 3 (0-9) | -- |
| Polypharmacy | < 5 medications | 384 (52.2%) | 72 (19.5%) | <0.01 |
| >= 5 medications | 352 (47.8%) | 297 (80.5%) | ||
| Difficulty with ADL | yes | 74 (9.9%) | 90 (24.5%) | <0.01 |
| no | 676 (90.1%) | 278 (75.5%) | ||
| Have someone take them to the doctor (social support) | yes | 671 (89.8%) | 352 (95.4%) | <0.01 |
| no | 79 (10.2%) | 17 (4.6%) | ||
| Impairment on GDS-15 | yes | NA | 84 (22.8%) | -- |
| no | -- | 285 (77.2%) | ||
| Cognitive impairment* | yes | 46 (6.1%) | 119 (32.2%) | -- |
| no | 703 (93.9%) | 250 (67.8%) | ||
| Albumin | Median (range) | 3.9 (1.0-5.0) | 3.6 (1-6.9) | -- |
| Creatinine clearance | Median (range) | 58.1 (12.3-122.9) | 64.2 (9.6-188) | -- |
Abbreviations: ADL, activities of daily living; GDS, Geriatric Depression Scale; GI, gastrointestinal; GU, genitourinary; KPS, Karnofsky Performance Scale; NA, not assessed; NR, not reported; SD, standard deviation.
*
Cognitive impairment was assessed through Blessed Orientation Memory Concentration test in the development cohort and Mini-Cog test in the validation cohort